(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
21 July 2011 (21.07.2011)

PCT

(10) International Publication Number
WO 2011/088188 A1

(51) International Patent Classification:
A61P 5/00 (2006.01) *A61K 31/55* (2006.01)
A61K 31/4188 (2006.01)

(21) International Application Number:
PCT/US2011/021100

(22) International Filing Date:
13 January 2011 (13.01.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/294,980 14 January 2010 (14.01.2010) US

(71) Applicant *(for all designated States except US)*: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **HU, Qi-Ying** [CN/US]; Novartis Institutes for BioMedical Research, Inc., 100 Technology Square, Cambridge, Massachusetts 02139 (US). **KSANDER, Gary** [US/US]; 37 The Flume, Amherst, New Hampshire 03031 (US). **MEREDITH, Erik** [US/US]; Novartis Institutes for BioMedical Research, Inc., 100 Technology Square, Cambridge, Massachusetts 02139 (US). **MONOVICH, Lauren G.** [US/US]; Novartis Institutes for BioMedical Research, Inc., 100 Technology Square, Cambridge, Massachusetts 02139 (US). **PAPILLON, Julien** [FR/US]; Novartis Institutes for BioMedical Research, Inc., 100 Technology Square, Cambridge, Massachusetts 02139 (US). **SCHUMACHER, Christoph** [CH/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH).

(74) Agent: **MULKEEN, Matthew**; Novartis, Patent Department, One Health Plaza, Bldg. 101, East Hanover, New Jersey 07936 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

(54) **Title**: USE OF AN ADRENAL HORMONE-MODIFYING AGENT



(I)

(57) **Abstract**: The present invention relates to a method of treating a disease or disorder characterised by increased stress hormone levels and/or decreased androgen hormone levels in a subject, comprising administering to the subject a therapeutically effective amount of a compound represented by formula (I): wherein n is 1 or 3; R is hydrogen or --C(O)N(R_a)(R_b) wherein R_a and R_b are independently --(C_1-C_4) alkyl, or --(C_1-C_4) alkyl-(C_5-C_7) aryl, wherein each of R_a and R_b is optionally substituted by --(C_1-C_4) alkoxy; R_1, R_2, and R_3, are independently hydrogen, halogen, cyano or --(C_6-C_{10}) aryl, wherein said --(C_6-C_{10}) aryl is optionally substituted by halogen, with the proviso that no more than one of R_1, R_2, and R_3 is hydrogen; and R_4 and R_5 are hydrogen; or a pharmaceutically acceptable salt thereof.

WO 2011/088188 A1